MariamTek finds profitable solutions for the biggest problems in healthcare and the environment.
MariamTek finds profitable solutions for the biggest problems in healthcare and the environment. We help these solutions reach the market by partnering with a combination of cash flow positive and near-profitable companies. We share the revenue with our licensees and devote a substantial portion of our remaining revenue to help develop promising new mid-stage technology that needs 3-5 years to reach the market.
Meeting our revenue goals therefore keeps our licensees happy because:
1) Licensees share in the annual revenue
2) They benefit from MariamTek’s expanding equity portfolio
3) License values increase for greater ROI and liquidity
4) Have access to discounts on future ILO launches
By developing revolutionary solutions that are set to shake global markets, we can mitigate the risk of biotechnology investment while achieving our vision of sustainable philanthropy. This is all made possible through careful selection, managed development and global deployment.
MariamTek is happy to announce a first year royalty payout for our original licensees of $2.00/license.
Diabetes Actual is a MariamTek spin-off seeking to restore metabolic wellness for diabetes patients around the world. We use clinically proven therapies to reverse the ravages of diabetes by restoring insulin sensitivity. This is made possible through partnership with the US-based company that developed this revolutionary treatment, Well Cell Global. Diabetes Actual seeks to deploy their FDA-approved, life-saving technology throughout the world.
Diabetes Actual’s pulsatile insulin protocol restores insulin sensitivity to cells, helping to ensure that maximal energy is generated. The results are decreased problems from the complications of diabetes including heart disease, stroke, neuropathy, Alzheimer’s, kidney function, erectile dysfunction and wound healing.
Diabetes Actual is licensing partnerships with regional distributors in the US, the Asia Pacific and GCC countries. Furthermore, there is a launch in the USA Midwest underway, and an imminent plan to launch a new PIR training facility in the GCC and/or India.
Through innovative financial planning, MariamTek has the potential to generate immediate revenue streams for our licensees. In addition, our ILO provides the funding required for the maturation of the next generation of blockbuster technologies.
The technology startups we work with have:
1) The potential for large returns
2) Transformative or disruptive solution
3) A platform technology with multiple applications
4) A short development time
5) A well demarcated regulatory pathway
6) A strong intellectual property position
7) Demonstrated safety
Additionally, we look at the global market potential including opportunities for regional manufacturing and distribution, recruitment of key opinion leaders among physicians, business people and government ministers. If the solution is related to healthcare, it ideally is a natural product (already in our bodies or in nature), be stable & easily transportable, while remaining affordable for all citizens.
We work with a variety of healthcare solutions, with a focus on prevention, treatment and restoration. These cover a range of sectors, including infectious disease, diabetes, atherosclerosis, cancer, tissue damage and aging/dementia. Examples of our technology discoveries include:
1) Pain-free micro-needle vaccination technology that provides an easy way to vaccinate the world at 1/10th the cost without cold chain dependency.
2) Our trauma treatment sector features solutions for the global blood bank shortage. Our LifePak is a blood bank in a backpack containing platelets and red blood cell substitutes. This highly portable kit is designed for trauma resuscitation at the scene of injury or in smaller rural hospitals and clinics. There’s no need for blood typing, refrigeration or technicians – helping to save lives.
3) The MG53 natural “molecular bandage” from Axolo repairs injury to cells, which preserves organs and saves lives. This has endless clinical uses such as for stroke, heart attacks, kidney failure, liver damage, lung damage, aging, ALS etc.
4) Pain control with a new non-opioid, first-in-class pharmaceutical agent from Cytometix. This product has an excellent safety profile, is non-addicting with few if any side effects. It controls pain on par with narcotics. The product can be administered via IV and oral routes and has significant anti-inflammatory effects. MariamTek is helping to raise funds for Cytometix to complete their regulatory studies to get to the market.
5) Natural melanin for a planet healthy sunscreen. Current sunscreens and cosmetic colorants contain harmful chemicals that can be toxic to humans and to coral reefs. Avisa Myko has patented a technique to extract large quantities of natural melanin from a marine organism. Their solution produces large quantities of natural melanin at 1/100th of the cost of current methods. This enables the addition of natural melanin into a wide range of products ranging from cosmetics (e.g. sunscreen, hair colorants) to medical applications (protection from radiation exposure) to aerospace (effective and light-weight shielding from cosmic radiation). MariamTek hopes to launch Avisa Myko on their own ILOCX platform this year.
6) Non-invasive, non-touch rapid diagnostics for viral infection (including Covid) and realtime blood glucose monitoring. The miniaturization of Hybrid Infrared Radio Frequency (HIRF) technology allows for the development of detection devices that can scan the body for many different proteins and chemicals. MariamTek is working with American Medical Solutions International (AMSI) based in Florida, USA. AMSI has developed the Covid Hunter™ and produced a prototype that determines your blood sugar level with a simple non touch scanning of your skin.
MariamTek has a range of environmental partners with solutions to help mitigate the negative effects of petroleum-based plastics and polyester. One of our key partners, Natural Fiber Welding (NFW), has developed a new circular chemical process that adds amazing strength and functionality to plant-based cellulose fibers.
This technology replaces the need for petroleum-based plastics and yarn and will transform the multi-trillion textile, leather-goods, shoe, luggage and furnishing industries. This results in products that are 100% recyclable or compostable. NFW’s technology unlocks the power of plants and supports their rallying cry, “Plants, Not Plastics™.
NFW has already received investment and/or formed partnerships with major fashion producers of polo shirts, shoes and luxury interiors for high end car makers. MariamTek is introducing NFW’s technology to various regions of the world through the supply of their eco-friendly materials to designers, artisans and manufacturers. MariamTek’s newest entity, Heather, Ltd. will supply Habitat Healthy Leather to India and the rest of Asia.
MariamTek has launched Heather, Ltd. to import and distribute NFW’s Mirum brand of plant-based leather that is 100% recyclable, has 0% petroleum content and handles and feels like animal skin leather.
The technology startups we work with ideally have the potential for large returns, a transformative or disruptive solution, a platform technology with multiple applications, a short development time, a well demarcated regulatory pathway, a strong intellectual property position and demonstrated safety.
Additionally we look at the global market potential including opportunities for regional manufacturing and distribution, recruitment of key opinion leaders among physicians, business people and government ministers. If the solution is related to healthcare, it ideally is a natural product (already in our bodies), be stable & easily transportable, while remaining affordable for all citizens.
Our ILO guarantees that when we make money - you make money.
ILO’s are not based on profits, but gross revenue, or all sales without any costs or taxes subtracted, therefore if you buy our ILO you will make money as we make sales.
These projections are provided by us, MARIAMTEK INC. If you agree they are realistic and achievable, buy our ILO today.
Commencement Date
Licenses Available
Current Allocation
Total Issued
per license, 10% royalty in year 1
per license, 10% royalty in year 2
per license, 10% royalty in year 3
In addition to paying you a royalty, at the end of the 3rd year MARIAMTEK INC can choose to extend the license for another 3 years, or buy the ILO back for cash should MARIAMTEK INC conduct a major financing.
ILO Value is the estimated value of your ILO in USD ($). This is calculated using our projected revenue numbers. Therefore if our revenue projections are realistic and achievable, this is a good estimation of the buy out price you should expect at different stages.
THIS AGREEMENT is between MARIAMTEK INC (“the Company”), - AND – The Buyer who is the Current License Holder, and who holds this license to promote the companies message to their audience with a view increasing their sales, which will in turn will increase the royalty to all license holders. The Buyer is determined by the Live Ledger held by ILOCX which holds details of licenses issued bought and sold (“the Buyer”).
January 30, 2021
Details of the Licensed Product are described on the Company’s page hosted on the site at www.ILOCX.com
None
Minimum Requirements for Qualification are a confirmed share of the Company’s information and Promotional Message on social media. This can be done on the ILOCX platform. Alternative ways to qualify are at the discretion of the company selling the license.
$10
Under the License Agreement the buyer is entitled to royalty payments once qualified
Each License receives a royalty equal to 10% of the Gross Revenues from the recorded and officially filed revenue, divided by 50,000, the total amount of ILO Units in the Initial License Offering. All royalties will be paid to the Buyer’s wallet on the ILOCX platform within 5 days of payment settlement from the company. These days will be announced prior to release.
This License is for an Initial Term of 3 years at which time the License can be extended by the issuing Company for a further 3 years, (a “Rollover”) and new terms may be set by the company at this time in line with ILOCX exchange rules and guidelines. Alternatively, the Company may offer to buy the License back from the Buyer (“a ‘Buyback”). The Company will give notice of Rollover terms or Buyback Price 90 days before the end of the Initial Term, as outlined in the Buyer Terms and Conditions.
All licenses must be valid and deemed qualified to benefit from the Royalty and the Rollover or Buyback.
This Agreement should be read in conjunction with the License Terms and Conditions, the Company Terms and Conditions, the Buyer Terms and Conditions and the ILOCX Terms of Use which form part of this entire Agreement, as well all ILOCX rules, policies, rulings and procedural requirements (collectively the “ILOCX Terms and Conditions”).
All parties have read and agreed to comply with the ILOCX Terms and Conditions, this Agreement, and any documents included by reference above. These may be amended from time to time and the parties will be notified by email of such amendments. Breach of any of the terms of this agreement may result in termination of this Agreement under the termination procedures outlined in the License Terms and Conditions.
This Agreement shall be governed by the laws of Delaware, USA and the parties exclusively submit to the jurisdiction of the Courts of Delaware, USA. In the event of any dispute, refer to the terms and conditions for the procedure.
Agreed on behalf of the Company:
The Company confirms its consent to this License Agreement by presenting the ILO for sale on the ILOCX platform.
Agreed on behalf of the Buyer:
The Buyer consents to this agreement by completing their order on ILOCX.
Diabetes Actual seeks to restore metabolic wellness through the use of proven therapies for reversing the ravages of diabetes by restoring insulin sensitivity.
TeaCo Biological Supply is on a mission to regenerate and restore the world's depleted soils.
LuxMods has emerged as a new leader in modular housing, with the modular home market is expected to grow to over 114 billion by 2028, and LuxMods projecting over $170 million in revenue in the next 3 years alone.
4D Vision was founded to develop revolutionary green power solutions, tackling the biggest challenges in renewable energy.
